Comparison of treatment costs of pembrolizumab versus nivolumab in head and neck squamous cell carcinoma.

被引：0
|
作者：
Yeh, Justin
Guddati, Achuta Kumar
机构：
[1] Med Coll Georgia, Augusta, GA 30912 USA
[2] Augusta Univ, Med Coll Georgia, Augusta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19368
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Carboplatin versus cetuximab chemoradiation in cisplatin ineligible locally advanced head and neck squamous cell carcinoma.
    Thanikachalam, Kannan
    Krishnan, Jayasree
    Siddiqui, Farzan
    Ali, Haythem Y.
    Sheqwara, Jawad
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] Pembrolizumab plus cetuximab with neoadjuvant chemotherapy for head and neck squamous cell carcinoma
    Yao, Zhuowei
    Wang, Jingshuo
    Jiang, Yongquan
    Zhang, Yi
    Liu, Jun
    Dai, Li
    Shen, Silin
    Zhou, Xiang
    Liu, Qiang
    Zheng, Luying
    Qian, Minfei
    Li, Jiping
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2025, 47 (01): : 289 - 299
  • [33] Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population
    Chen, Wen-Chun
    Chu, Pen-Yuan
    Lee, Yu-Ting
    Lu, Wen-Bin
    Liu, Chun-Yu
    Chang, Peter Mu-Hsin
    Yang, Muh-Hwa
    MEDICINE, 2017, 96 (52)
  • [34] Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinoma
    Desilets, Antoine
    Soulieres, Denis
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (08) : 927 - 933
  • [35] Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC).
    Haddad, Robert I.
    Seiwert, Tanguy Y.
    Chow, Laura Quan Man
    Gupta, Shilpa
    Weiss, Jared
    Gluck, Iris
    Eder, Joseph Paul
    Burtness, Barbara
    Tahara, Makoto
    Keam, Bhumsuk
    Kang, Hyunseok
    Muro, Kei
    Albright, Andrew
    Huang, Lingkang
    Ayers, Mark
    Mogg, Robin
    Cristescu, Razvan
    Cheng, Jonathan D.
    Mehra, Ranee
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] Efficacy of chemotherapy after progression with nivolumab in squamous cell carcinoma of the head and neck
    Suzuki, Shinsuke
    Toyoma, Satoshi
    Tomizawa, Hiroki
    Yamada, Toshiki
    Iikawa, Nobuko
    Shiina, Kazuhiro
    Saito, Hidekazu
    Koizumi, Koh
    Kawasaki, Yohei
    Yamada, Takechiyo
    AURIS NASUS LARYNX, 2020, 47 (03) : 485 - 488
  • [37] Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck
    Klein, Oliver
    JAMA ONCOLOGY, 2024, 10 (01) : 143 - 144
  • [38] Inflammatory Arthritis Induced by Pembrolizumab in a Patient With Head and Neck Squamous Cell Carcinoma
    Spathas, Nikolaos
    Economopoulou, Panagiota
    Cheila, Myrto
    Kotsantis, Ioannis
    Fanouriakis, Antonis
    Kassara, Dimitra
    Psyrri, Amanda
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [39] CARBOPLATIN, PACLITAXEL AND PEMBROLIZUMAB FOR THE FIRST LINE TREATMENT OF RECURRENT AND/OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
    Valadez, Angelica
    Welsh, Madeleine
    Kim, Christine
    Johns, Angela
    Algazi, Alain
    Kang, Hyunseok
    Kang, Hyunseok
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A118 - A118
  • [40] Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma
    Inoue, Hiroto
    Yokota, Tomoya
    Hamauchi, Satoshi
    Onozawa, Yusuke
    Kawakami, Takeshi
    Shirasu, Hiromichi
    Notsu, Akifumi
    Yasui, Hirofumi
    Onitsuka, Tetsuro
    AURIS NASUS LARYNX, 2020, 47 (04) : 650 - 657
12345